Correlation of bilirubin and toxic bile acids in critically ill patients with cholestatic liver dysfunction and adsorber application.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 Sep 2024
18 Sep 2024
Historique:
received:
21
12
2023
accepted:
10
09
2024
medline:
19
9
2024
pubmed:
19
9
2024
entrez:
18
9
2024
Statut:
epublish
Résumé
Bilirubin is one of the most frequently used laboratory values to monitor critically ill patients with cholestatic liver dysfunction. Besides bilirubin, toxic bile acids (TBAs), which may cause severe organ damage, are typically elevated. A correlation between both parameters seems plausible, but data are lacking. The aim was to investigate whether there is a correlation between bilirubin and TBAs in patients' blood and whether a compareable reduction can be observed during the use of the adsorber CytoSorb (CS). As part of the Cyto-SOLVE study (NCT04913298), 16 critically ill patients with cholestatic liver dysfunction, bilirubin concentration > 10 mg/dl, continuous kidney replacement therapy and CS-application were investigated. Bilirubin and TBA concentrations were measured from arterial blood at defined time points (before start, after 6 and 12 h). Relative reduction (RR) was calculated using the formula[Formula: see text]. A moderate to high correlation between bilirubin and TBA concentration at all defined timepoints (r
Identifiants
pubmed: 39294181
doi: 10.1038/s41598-024-72676-6
pii: 10.1038/s41598-024-72676-6
doi:
Substances chimiques
Bilirubin
RFM9X3LJ49
Bile Acids and Salts
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
21762Informations de copyright
© 2024. The Author(s).
Références
Pierrakos, C. et al. Increased mortality in critically ill patients with mild or moderate hyperbilirubinemia. J. Crit. Care40, 31–35 (2017).
doi: 10.1016/j.jcrc.2017.01.017
pubmed: 28314169
Horvatits, T. et al. Circulating bile acids predict outcome in critically ill patients. Ann. Intensive Care7(1), 48 (2017).
doi: 10.1186/s13613-017-0272-7
pubmed: 28466463
pmcid: 5413465
Perez, M. J. & Briz, O. Bile-acid-induced cell injury and protection. World J. Gastroenterol.15(14), 1677–1689 (2009).
doi: 10.3748/wjg.15.1677
pubmed: 19360911
pmcid: 2668773
Vitek, L., Hinds, T. D., Stec, D. E. & Tiribelli, C. The physiology of bilirubin: health and disease equilibrium. Trends Mol. Med.29(4), 315–328 (2023).
doi: 10.1016/j.molmed.2023.01.007
pubmed: 36828710
pmcid: 10023336
Bilirubin inhibits bile acid induced apoptosis in rat hepatocytes.pdf>.
Scharf, C. et al. Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study. Sci. Rep.11(1), 10190 (2021).
doi: 10.1038/s41598-021-89712-4
pubmed: 33986443
pmcid: 8119427
Riva, I., Marino, A., Valetti, T. M., Marchesi, G. & Fabretti, F. Extracorporeal liver support techniques: a comparison. J. Artif. Organs (2023).
Akoglu, H. User’s guide to correlation coefficients. Turk. J. Emerg. Med.18(3), 91–93 (2018).
doi: 10.1016/j.tjem.2018.08.001
pubmed: 30191186
pmcid: 6107969
Juschten, J. et al. Incidence, clinical characteristics and outcomes of early hyperbilirubinemia in critically ill patients: insights from the mars study. Shock57(2), 161–167 (2022).
doi: 10.1097/SHK.0000000000001836
pubmed: 34238904
Sullivan, J. I. & Rockey, D. C. Diagnosis and evaluation of hyperbilirubinemia. Curr. Opin. Gastroenterol.33(3), 164–170 (2017).
doi: 10.1097/MOG.0000000000000354
pubmed: 28333690
Perez, R. et al. Critical care hepatology: definitions, incidence, prognosis and role of liver failure in critically ill patients. Crit. Care26(1), 289 (2022).
doi: 10.1186/s13054-022-04163-1
Jenniskens, M., Langouche, L., Vanwijngaerden, Y.-M., Mesotten, D. & Van den Berghe, G. Cholestatic liver (dys)function during sepsis and other critical illnesses. Intensive Care Med.42(1), 16–27 (2016).
doi: 10.1007/s00134-015-4054-0
pubmed: 26392257
Guicciardi, M. E. & Gores, G. J. Bile acid-mediated hepatocyte apoptosis and cholestatic liver disease. Dig. Liver Disease34(6), 387–392 (2002).
doi: 10.1016/S1590-8658(02)80033-0
Voiosu, A. M. et al. Total bile acid levels are associated with left atrial volume and cardiac output in patients with cirrhosis. Eur. J. Gastroenterol. Hepatol.30(4), 392–397 (2018).
doi: 10.1097/MEG.0000000000001043
pubmed: 29227330
Ocskay, K. et al. Uncertainty in the impact of liver support systems in acute-on-chronic liver failure: a systematic review and network meta-analysis. Ann. Intensive Care11(1), 10 (2021).
doi: 10.1186/s13613-020-00795-0
pubmed: 33462764
pmcid: 7813174
Perino, A., Demagny, H., Velazquez-Villegas, L. & Schoonjans, K. Molecular physiology of bile acid signaling in health, disease, and aging. Physiol. Rev.101(2), 683–731 (2021).
doi: 10.1152/physrev.00049.2019
pubmed: 32790577
Hui, W. F., Cheung, W. L., Chung, F. S., Leung, K. K. Y. & Ku, S. W. The successful application of hemoadsorption for extracorporeal liver support in a child with acute liver failure. Int. J. Artif. Organs45(10), 878–882 (2022).
doi: 10.1177/03913988221116135
pubmed: 35918853
Dhokia, V. D., Madhavan, D., Austin, A. & Morris, C. G. Novel use of cytosorb haemadsorption to provide biochemical control in liver impairment. J. Intensive Care Soc.20(2), 174–181 (2019).
doi: 10.1177/1751143718772789
pubmed: 31037112
Popescu, M. et al. Artificial liver support with cytosorb and mars in liver failure: a retrospective propensity matched analysis. J. Clin. Med. ; 12(6). (2023).
Dominik, A. & Stange, J. Similarities, differences, and potential synergies in the mechanism of action of albumin dialysis using the mars albumin dialysis device and the cytosorb hemoperfusion device in the treatment of liver failure. Blood Purif.50(1), 119–128 (2021).
doi: 10.1159/000508810
pubmed: 32615564